Particle News: Latest Eli Lilly and Company news

U.S. Markets Close Holiday Week Deep in the Red as Volatility Persists

Major indices tumbled further, with corporate earnings shocks and trade policy uncertainty amplifying investor concerns.

Markets Steady as Trade Talks Progress and Earnings Drive Sector Swings

Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials

Stories older than 24h

Leqembi Approved by European Regulators for Early-Stage Alzheimer's Treatment

Pfizer Halts Development of Danuglipron After Liver Safety Concerns

Verve-102 Gene-Editing Therapy Shows Promising LDL Cholesterol Reduction in Early Trial

Pfizer Halts Development of Oral Weight-Loss Pill After Liver Injury

CMS Rejects Medicare and Medicaid Coverage for Anti-Obesity Drugs

Hims & Hers Expands Weight-Loss Offerings with New Medications

Eli Lilly Sues Strive and Empower Over Unapproved Tirzepatide Products

Isomorphic Labs Secures $600M to Advance AI-Driven Drug Discovery

Eli Lilly’s Lepodisiran Achieves 94% Reduction in Genetic Heart Disease Risk Factor in Phase 2 Trial

EU Regulators Reject Eli Lilly's Alzheimer's Drug Over Safety Concerns

Novo Nordisk Faces Investor Turmoil as Wegovy Sales and Market Share Decline

Eli Lilly's Mounjaro Launches in India, Targeting Obesity and Diabetes

Novo Nordisk Acquires Chinese Obesity Drug After CagriSema Trial Disappointment

Eli Lilly Launches Mounjaro in India to Address Obesity and Diabetes

Roche and Zealand Partner in $5.3 Billion Deal for Obesity Drug Development

Senators Question RFK Jr.'s Mar-a-Lago Dinners with Big Pharma Executives

Amgen Advances Weight-Loss Drug MariTide with Two Phase 3 Trials

Pfizer Considers Relocating Overseas Manufacturing to U.S. Facilities

Eli Lilly Targets Unapproved Weight-Loss Drugs with New Ad Campaign

Eli Lilly Announces $27 Billion Investment in U.S. Manufacturing Expansion

Eli Lilly Expands Zepbound Access with New Doses and Lower Prices

FDA Declares Semaglutide Shortage Over, Impacting Compounded Drug Market

Eli Lilly Reports Mixed Q4 Results as Key Drug Sales Fall Short of Expectations

Novo Nordisk Reports Doubling Wegovy Sales, Projects Slower Growth in 2025

Minnesota Secures $35 Monthly Insulin Cap in Landmark Settlement with Novo Nordisk

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

Google DeepMind Spinoff Plans AI-Designed Drug Trials by Year-End

Tech Rally and Rate-Cut Hopes Propel Wall Street to Weekly Gains

Eli Lilly Lowers 2024 Revenue Forecast as Weight-Loss Drug Sales Lag

Eli Lilly Lowers 2024 Revenue Forecast Due to Slower Weight-Loss Drug Growth

Medicare to Cover Eli Lilly’s Zepbound for Sleep Apnea Treatment

FDA Ends Shortage of Tirzepatide, Restricts Compounded Weight-Loss Drugs

FDA Approves Zepbound as First Drug Treatment for Sleep Apnea

Novo Nordisk Shares Plunge After Weight-Loss Drug Trial Falls Short

GLP-1 Drugs Revolutionize Prescriptions and Broader Health Applications

FDA Ends Shortage of Eli Lilly’s Weight-Loss Drug, Restricts Copycat Versions

Merck Secures $2 Billion Deal for Experimental Oral Weight Loss Drug from Hansoh Pharma

Eli Lilly Partners with Ro to Expand Access to Lower-Cost Zepbound Vials

Scams and Counterfeits Exploit Demand for Weight-Loss Drugs

Eli Lilly Announces $3 Billion Wisconsin Manufacturing Expansion

NHS to Gradually Roll Out Mounjaro Weight-Loss Drug Over 12 Years

Zepbound Outperforms Wegovy in Weight Loss Clinical Trial

Government Plans Dominate Coverage for Costly Weight-Loss Drugs

Eli Lilly's Oral Drug Shows Promise in Lowering Genetic Cholesterol

Eli Lilly and Johnson & Johnson Challenge US Over 340B Drug Discount Program

Supply and Cost Challenges Persist for Popular Weight-Loss Drugs

Eli Lilly Shares Plunge After Disappointing Q3 Earnings and Sales

Global Stocks Decline as Chipmakers Struggle, Gold Reaches New High

NHS Rejects Alzheimer’s Drug Donanemab Despite Promising Results

Eli Lilly Sues Vendors for Selling Unauthorized Tirzepatide Products

UK Government Proposes Weight Loss Injections for Overweight Unemployed

UK Government Trials Weight-Loss Jabs to Tackle Unemployment

FDA Reconsiders Ban on Compounded Versions of Eli Lilly's Weight Loss Drug

Senator Warren Urges FTC to Scrutinize Novo Holdings' $16.5B Catalent Acquisition

Eli Lilly Fights Back Against Compounded Tirzepatide Amid FDA Supply Resolution

Texas Sues Insulin Manufacturers and PBMs for Price Inflation

FDA Declares End to Tirzepatide Shortage, Impacting Compounded Drug Market

Eli Lilly to Invest $4.5 Billion in New Indiana Drug Manufacturing Facility

Roche Accelerates Obesity Drug Development, Projects $3.6 Billion in Annual Sales

FTC Sues Top Pharmacy Benefit Managers Over Inflated Insulin Prices

Eli Lilly Invests $1.8 Billion to Expand Drug Production in Ireland

Weight-Loss Drug Tirzepatide More Effective in Women, Study Finds

Eli Lilly Names Lucas Montarce as New CFO Amid Expansion Efforts

Eli Lilly Introduces Affordable Zepbound Vials to Address Obesity Drug Shortage

Eli Lilly's Tirzepatide Shows 94% Reduction in Diabetes Risk

Compounded Weight Loss Drugs Raise Safety and Ethical Concerns

Eli Lilly's Weight-Loss Drugs Drive Record Q2 Revenue Surge

Eli Lilly's Q2 Earnings Surge on High Demand for Weight-Loss Drugs

Eli Lilly's Zepbound Shows Promise in Reducing Heart Failure Risks

Roche Accelerates Development of Promising Weight-Loss Pills

Viking Therapeutics Advances Weight-Loss Drug, Shaking Up Market Leaders

NBC to Air First-Ever Commercial-Free Hour During Paris Olympics Opening Ceremony

Roche's New Weight Loss Pill Shakes Up Pharmaceutical Market

Pfizer Advances Daily Weight Loss Pill Amid FDA Rejection of Novo's Insulin

Eli Lilly Acquires Morphic for $3.2 Billion

Eli Lilly's Mounjaro Outperforms Novo Nordisk's Ozempic in Weight Loss Study

Biden and Sanders Demand Lower Prices for Popular Weight-Loss Drugs

FDA Approves Donanemab: A Breakthrough in Early Alzheimer’s Treatment

Weight-Loss Drug Market Expands with New Generic Versions

Weight-Loss Drug Tirzepatide Shows Promise for Treating Sleep Apnea

WHO and Eli Lilly Warn of Dangerous Fake Weight-Loss Drugs

Michigan's Largest Insurer Ends Coverage for Costly Weight-Loss Drugs

FDA Panel Recommends Approval of Promising Alzheimer's Drug Donanemab

FDA Reviewers Weigh Safety and Approval Scope for Eli Lilly’s Alzheimer’s Drug

Alphabet Appoints Anat Ashkenazi as New CFO Amid AI Expansion

UK Approves Mounjaro for Obesity Treatment, Offering Alternative to Wegovy

Eli Lilly Invests $9 Billion to Boost Production of Weight Loss Drugs

Eli Lilly's Weekly Insulin Matches Effectiveness of Daily Doses in Trials

Novo Nordisk to Investigate Ozempic's Impact on Alcohol Consumption

AlphaFold 3 Revolutionizes Molecular Science with Advanced Predictive Capabilities

Weight-Loss Drug Market Heats Up as Prices Drop and New Treatments Emerge

Eli Lilly's Q1 Earnings Surge on Strong Zepbound and Mounjaro Sales

Global Stocks Face First Monthly Decline of 2024 Amid Interest Rate Concerns

Eli Lilly Faces Zepbound Shortage, Impacting Weight Loss and Diabetes Patients

Eli Lilly's Zepbound Shows Promise in Treating Sleep Apnea and Obesity

Altimmune's Weight Loss Drug Shows Promising Results in Minimizing Muscle Loss

Viking Therapeutics' Weight Loss Drug Shows Promise in Early Trial